By Frank Vinluan – MedCity News –
Autolus Therapeutics’ Aucatzyl is now FDA approved for treating advanced cases of B-cell precursor acute lymphoblastic leukemia. While it goes after the same target as Gilead Sciences’ Tecartus, Autolus engineered its CAR T-therapy with properties that could improve safety, efficacy, and durability.
An Autolus Therapeutics cell therapy has won FDA approval for treating an aggressive blood cancer. It’s the biotech’s first approved product and just the second CAR T-treatment for adults who have this particular malignancy. But compared to that other cell therapy and other treatments available, Autolus’s therapy has features that could set it apart from the field.
